Corcept醫療 CORT 深 滬
已收盤 02-06 16:00:00 美东时间
40.83
+2.470
+6.44%
華盛通- 最 高40.846
- 今 開39.01
- 成交量 138.45万股
- 最 低 38.68
- 昨 收 38.36
- 總市值 42.95亿
- 52周最高 117.33
- 市盈率 靜 33.16
- 換手率 1.32%
- 52周最低 32.9906
- 委 比 -83.65%
- 總股本 1.05亿
- 歷史最高 117.33
- 量 比 0.61
- 振 幅 5.65%
- 歷史最低 1.27
- 每 手 1
- 風險率 12.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
Corcept down as FDA revises rejection letter for hormonal disorder therapy
Corcept Therapeutics (CORT) lost ~16% in the premarket on Friday after the FDA revised a Complete Response Letter issued last month in connection with the company’s marketing application for its hormo...
01-30 22:19
BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings
BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings ** Shares of drugmaker Corcept Therapeutics CORT.O fall 16.5% to $37.25 premarket ** Last year, the U.S. FDA declined to approve Corcept's drug application for relacorilant to treat hypertension in Cushing's syndrome patients
01-30 21:30
美股盘后 | Corcept医疗跌17.12%
Corcept医疗公布了Phase 1b/2开放标签临床试验的最新进展，公司正积极推进相关临床试验工作，这将可能影响其未来的产品管线布局和市场竞争地位。
01-30 05:42
Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions
Corcept Therapeutics ($CORT) announced an update on their ongoing clinical stud...
01-29 00:31
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Expert Outlook: Corcept Therapeutics Through The Eyes Of 5 Analysts
In the preceding three months, 5 analysts have released ratings for Corcept The...
01-23 20:00
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $105
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $90 to $105.
01-23 18:04
Corcept医疗(CORT.US)抗癌小分子关键3期结果公布 有望明年上市
此前，美国FDA已受理relacorilant用于治疗铂耐药卵巢癌的上市申请，并设定PDUFA日期为2026年7月11日。
01-23 07:46
